As Per the Report, the Size of the Platelet Aggregation Devices Market in the Middle East & Africa is valued at USD 21.72 million in 2022 and is estimated to be growing at a CAGR of 15.51%, to reach USD 44.66 million by 2027 during the forecast period 2022 to 2027.
Potential drivers for this market include a vast unmet demand for platelet testing programs to identify diseases like HIV, dengue, etc., in the Middle East and African regions. In addition, there is an apparent market demand among those on antiplatelet therapy for many diseases. Since this is a medical device market, fundamental growth forces would depend on product characteristics such as precise control of platelet thrombus's extent and spatial location, sample volumes, blood flow requirements, multiple clinical assessments, and proper streamlined procedures. In addition, platelet aggregation devices have a wide range of applications in diagnosing various diseases, detecting platelet dysfunction and associated disorders. Surgical assessment of bleeding risk, identification of genetically acquired platelet defects will further enhance the demand for the market.
According to the Center for Disease Control (CDC), dengue is endemic in more than 100 countries in APAC, the Americas, Africa, and the Caribbean. On average, 78 million cases of dengue fever occur worldwide each year. It is estimated that over 250 million people will be affected by malaria worldwide in 2024. The risk of malaria is high in poor, tropical, and subtropical regions of the world, hence posing a risk for healthcare. In 2019, around 55 to 60 million people lived with HIV worldwide, and approximately 44% of patients went undiagnosed. Therefore, there is an increasing demand for platelet function tests for the diagnosis of these diseases.
The high cost of devices, procedural limitations, and the lack of well-trained and trained professionals are some of the most notable. Specialized platelet aggregation devices are usually costly. It will be increased further by the associated expenses for reagents, accessories, and consumables, and maintenance costs; this is restraining the market.
This research report on the Middle East & Africa Platelet Aggregation Devices Market has been segmented and sub-segmented into the following categories
By End User:
Geographically, the Africa dominates the MEA platelet aggregation device market, followed by the Middle East region. Africa is the most significant contributor to most of the area, owing to the spread of malaria, dengue, and HIV, making it an attractive target for companies involved with platelet aggregation devices.
Moreover, the epidemic diseases such as dengue and malaria affect a large population in the region, the awareness of doctors, the increase in health tourism, the rise in the number of hospitals and laboratories in emerging countries will help the market. As a result, most major manufacturers are present in the region to provide for the unmet market needs.
Due to unfavorable health reforms in the MEA region, reduced reimbursement for platelet aggregation testing continued pressure to increase the use of existing equipment. A limited number of reference laboratories offering platelet aggregation testing in MEA will deliver limited market revenues. The African market is expected to experience significant growth at a CAGR of 6.5% during the forecast period.
The UAE platelet aggregation device market will provide a lucrative market in the projected period. A growing number of the pediatric population, the increased risk of target diseases, and the increased demand for platelet screening programs for the diagnosis of HIV are all contributing to the market's growth in this region.
KEY MARKET PLAYERS
Key Market Companies dominating the Middle East & Africa Platelet Aggregation Devices Market are Accriva Diagnostics, Helena Laboratories Corporation, BioData Corporation, Haemonetics Corporation, Siemens AG, Sysmex Corporation, Sentinel CH. S.p.A., Tem Group and Aggredyne, Inc.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com